Julie Trulson

Julie Trulson currently serves as the Vice President and Head of CMC, where she is responsible for overseeing the drug supply activities across various portfolios, encompassing process development, manufacturing, and distribution of clinical trial materials. She brings a wealth of experience, with over 25 years in clinical and commercial stage biopharmaceutical development within both biotechnology and pharmaceutical companies. Before joining Asher Bio, she was instrumental at Allogene in building and leading CMC cross-functional teams. Her role involved defining strategies for allogenic cell therapy drug programs and ensuring the delivery of clinical supplies. Previously, Trulson was the Executive Director, Head of Process Development and Manufacturing at OncoMed, where she managed a significant pipeline of partnered clinical stage biologic candidates, primarily focusing on oncology and immuno-oncology. Her earlier career includes holding scientific positions in Process Development at notable companies such as Amgen, Boehringer Ingelheim, and Abgenix, where she focused on biologic formulation development and drug product manufacturing/site transfers. Notably, she led cross-functional product teams and served as the global technical leader for Vectibix® during its launches in the US and internationally, managing all related regulatory filings, approvals, and global post-launch regulatory submissions. Trulson holds a Ph.D. in Chemistry from the University of California, Santa Cruz, and a B.S. in Biochemistry from Washington State University.